Elite Pharmaceuticals, Inc.
ELTP
$0.5475
-$0.0074-1.33%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -10.82M | -4.31M | -17.99M | -6.39M | 19.58M |
| Total Depreciation and Amortization | 2.07M | 2.12M | 2.10M | 1.96M | 1.74M |
| Total Amortization of Deferred Charges | 14.00K | 14.00K | 10.50K | 7.00K | 3.50K |
| Total Other Non-Cash Items | 49.15M | 24.80M | 25.01M | 16.59M | -10.36M |
| Change in Net Operating Assets | -21.33M | -15.17M | -3.50M | -7.86M | -8.35M |
| Cash from Operations | 19.09M | 7.46M | 5.64M | 4.31M | 2.62M |
| Capital Expenditure | -1.06M | -1.63M | -1.27M | -1.68M | -1.59M |
| Sale of Property, Plant, and Equipment | 110.00K | 125.30K | 125.30K | 125.30K | 15.30K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -900.00K | -900.00K | -900.00K | -900.00K |
| Cash from Investing | -954.70K | -2.40M | -2.05M | -2.46M | -2.47M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Debt Repaid | -4.80M | -845.00K | -1.09M | -934.20K | -793.00K |
| Issuance of Common Stock | 19.30K | 19.30K | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -4.78M | -825.70K | -1.09M | -934.20K | -793.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 13.35M | 4.23M | 2.50M | 922.50K | -646.60K |